TransEnterix CFO experienced in IPOs
Written on January 27, 2010
Durham medical device company TransEnterix has named a medical device industry veteran chief financial officer.
David Gill's experience includes work as CFO of several companies, including NxStage Medical (Nasdaq: NXTM), CTI Molecular Imaging, and Novoste Corp. (Nasdaq: NOVT). CTI Molecular Imaging was acquired in 2005 by Siemens Medical Solutions USA Inc. for $1 billion.
Gill has led three initial public offerings and raised more than $500 million in equity capital. In his role at TransEnterix, he has managed the company's $55 million Series B financing, which closed in October. The company is using proceeds from that round to commercialize its SPIDER technology, a surgical system that is less invasive than current methods no fax payday loan. The system allows laproscopic surgery to be performed through a single incision in the abdomen instead of the four or five typically required.
Gill holds a a bachelor’s degree in accounting from Wake Forest University and an MBA from Emory University.
TransEnterix employs more than 30 and plans to scale up to 80 or more by the end of 2010.
Filed in: management.